



Australian Government

Department of Health

Office of the Gene Technology Regulator

NOTIFICATION OF APPLICATION

Receipt of licence application from VRT Pharmaceuticals Pty Ltd for a clinical trial of a genetically modified virus for cancer treatment

The Office of the Gene Technology Regulator (OGTR) has received a licence application (DIR 187) from VRT Pharmaceuticals Pty Ltd to conduct a clinical trial of a genetically modified *Getah virus* as a treatment for cancer. A summary of the application is posted on our website (search for [DIR 187](#)).

The clinical trial is proposed to take place at Flinders Private Hospital in Bedford Park, South Australia over a period of 5 years. Up to twelve patients would receive seven doses of the GMO over a three month period, with the aim to evaluate the treatment's safety and tolerability. Patients who respond well to the treatment would have the opportunity to continue for an additional two years after the study protocol is complete.

The OGTR is preparing a Risk Assessment and Risk Management Plan for the application. This is expected to be released for public comment and advice from experts, agencies and authorities in late November 2021. There will be at least 30 days for submission of comments.

If you have any questions or would like to receive a copy of the full application or the summary, please contact the OGTR and quote reference number DIR 187.

Office of the Gene Technology Regulator

MDP 54 GPO Box 9848 CANBERRA ACT 2601

Telephone: 1800 181 030 E-mail: ogtr@health.gov.au

[OGTR website](#)

Dr Raj Bhula
Gene Technology Regulator
27 September 2020